Reddit Posts
$GANX Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Mentions
Been following the GANX JOURNEY FOR 4+ years and accumulating!!! Could be a UNICORN FOR MAN KIND- and if it helps the pocketbook GRAVY
That’s a fair take, but it misses what Gain Therapeutics is actually signaling with their capital structure and trial design. They aren’t trying to fund a Phase 2 or 3 internally, that’s intentional. The company strategically left enough cash runway to complete their biomarker data readout and advance the asset to a Phase 2 ready stage, because that’s the inflection point where strategic partnerships or outright acquisition deals usually happen in biotech. Management has been clear that their goal is not to dilute shareholders to fund a multi year, multimillion dollar Phase 2 or 3. Instead, they’re positioning GT-02287 to be de-risked, showing both safety and early efficacy signals, right before larger pharma steps in. This is the same approach used in many CNS and rare disease deals where early proof of mechanism drives billion dollar valuations, like we’ve seen with Denali, Cerevel, and Neurocrine. As for competition, yes, others are in the race, but GANX has shown actual functional improvement, including patients regaining sense of smell, reduced tremors, and improved balance. Those outcomes are something no other Parkinson’s therapy has achieved so far. They point to disease modification, not just symptom relief. If the upcoming biomarker data confirms blood brain barrier penetration and reduction of alpha synuclein, they’ll have something the rest of the field doesn’t, real proof of disease modifying effect in humans. So the low insider buying narrative misses the bigger picture. Management isn’t betting on long term internal development, they’re betting on a near term strategic transaction once the data validates the science.
Goldman Sachs just appeared as a market maker for $GANX, normally that’s just a liquidity move, not an endorsement. But the timing stands out: new corporate deck confirms biomarker + functional data due by year-end, after patients in the Phase 1b trial regained smell, reduced tremors, regained balance & motor control and chose to extend treatment another 9 months. Volume has surged, and if biomarkers confirm blood brain barrier penetration and α-synuclein reduction, we’re looking at potential disease-modifying evidence in Parkinson’s, something no drug has achieved yet. Not financial advice, but the setup heading into December is hard to ignore.
Shorting a $2 biotech with real, observable patient improvement, imminent biomarker confirmation, and a $75M market cap in a field where less advanced Parkinson’s assets were bought for $800M–$1B is a dangerous game. Gain Therapeutics ($GANX) may be sitting on the first disease-modifying therapy for Parkinson’s. Patients in the Phase 1b already showed regained smell, improved balance, and reduced tremors, things that can’t be explained by placebo or symptomatic relief. That implies underlying disease reversal. The next 4–6 weeks bring biomarker data confirming whether the drug crosses the blood-brain barrier and reduces α-synuclein, a key trigger for Parkinson’s. If confirmed, a buyout or partnership becomes almost inevitable given how small the company’s valuation is relative to the potential. At $2/share, risk for shorts is massive. There’s limited downside, but unlimited upside, a short squeeze could send this soaring quickly once data drops or partnership chatter heats up. Even a rumor can spark momentum when the float is this low.
The big fish are in a much better position to carry out phase 2 & 3. With GANX, the question is who will be the highest bidder to own the first drug that stops and even reverses to some extent the progression of Parkinson’s disease. A couple large pharmas cannot afford to let their competition own it.
GENE MACK CEO OF GAIN (GANX) is the daddy mack.. i have been invested in this for 4+ years and its coming to fruition on human and pocket books levels!!
There's a lot of good information on their website. You can start here: [https://gaintherapeutics.com/science-and-technology/science/](https://gaintherapeutics.com/science-and-technology/science/) Also, check out their November update: [https://gaintherapeutics.com/wp-content/uploads/2025/11/Corporate-Deck-GANX-November-NA.pdf](https://gaintherapeutics.com/wp-content/uploads/2025/11/Corporate-Deck-GANX-November-NA.pdf)
Check out this interview of the CEO of GANX... this is a conservative guy normally, so his confidence and excitement is telling. He knows what they have: [https://www.youtube.com/watch?v=CJcH-n6iKVU&t=380s](https://www.youtube.com/watch?v=CJcH-n6iKVU&t=380s)
Anyone interested in the science, there’s good information here in their November corporate update: https://gaintherapeutics.com/wp-content/uploads/2025/11/Corporate-Deck-GANX-November-NA.pdf
$GANX $4 call exp 9 days
GANX $2 call mad cheap right now for oct
GANX incredibly cheap option, share price has been having +5% days for the past week and a half
GANX final boarding call. Get in and get your gain.
GANX is going to be the next hot thing. Get in if you want your Gains!
$GANX up on BIG volume today. I have a post here from a few weeks ago, but it may be getting legs leading up to big Parkinson’s trial results in June.
GRTS phase and 2 read out on August 2 GANX phase 1 read out this August
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BUZZ GANX. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BUZZ GANX. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
PCSA and GANX. Speculative plays. Gain because they have some really big names involved for a company with no proven products right at the IPO. Processa because I did an internship ages ago for a different company whose IP Processa acquired. My old boss was always so damned hype on a few of their drugs going big that I've always kept an eye on it. I'm down on Gain at the moment, but it's pharma so nothing matters until a drug is proven/approved. I made a good bit of money on Processa selling in March and have recently rebought a ton this month. These are developmental/speculative pharma plays so they could moon or literally vanish overnight. Super risky.